argenx Shares Slump as $210M Volume Ranks 457th; Webinar to Spotlight MuSK Agonist Pipeline

On August 19, 2025, argenx (ARGX) closed with a 0.67% decline, trading at a daily volume of $0.21 billion, ranking 457th among stocks on the day. The biotech firm announced plans to host an R&D webinar on September 16 to spotlight its MuSK agonist candidate, ARGX-119, which is being developed for neuromuscular disorders including congenital myasthenic syndromes, amyotrophic lateral sclerosis, and spinal muscular atrophy. The session will feature presentations from company leadership and key opinion leaders, offering insights into the drug’s therapeutic potential and pipeline strategy.

The webinar marks the first in a series of events aimed at highlighting argenx’s research and development initiatives. Investors were provided access details for live and archived webcasts via the company’s investor relations portal. The move underscores argenx’s focus on advancing its autoimmune disease portfolio, particularly its neonatal Fc receptor blocker, while maintaining transparency around experimental programs in earlier stages of development.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.